Report / Paper metadata
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Source and limits
Source: PubMed. Stored source metadata; check the linked original before acting.
Bibliographic/status field selection only; abstracts, full text, contact fields and unselected fields omitted. No clinical interpretation.
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Identifier
- PMID 41732954
- Journal
- Oncoimmunology
- Kind
- Paper metadata